Adapting The Adpkd Outcomes Model to Predict Cost Consequence In Italian Patients With Autosomal Dominant Polycystic Kidney Disease (Adpkd) Treated With Jinarc (Tolvaptan).

ADPKD (Autosomal Dominant Polycystic Kidney Disease) is a severe genetic disorder with an estimated prevalence less than 4 patients per 10.000 inhabitants in EU. (1). ADPKD is characterised by the formation of renal cysts, which progressively compress normal tissue with loss of renal function and damage to adjacent tissues (2, 3). With progression of the disease patients reach the terminal stage (ESRD) of chronic kidney disease. (4) There is currently no overall consensus regarding prediction of the rate of progression in ADPKD, especially in the early stage of disease largely due to the high degree of inter-patient variability. (5)